NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Attralus

Attralus

Private
Naples, FloridaHealthcare & Life Scienceshttps://attralus.com/

Last Round

Series B

Extension

Feb 6, 2024

Est. Valuation

$426M

Total Funding Raised

$197M

Company Overview

Attralus is a biotechnology company that develops immunotherapies and imaging diagnostic platforms for the treatment of systemic amyloid diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

systemic amyloidosisAL amyloidosisbiopharmaceuticalfusion proteinorphan drugmolecular imagingradiotracersamyloid fibrilsbiotechdrug pipelineclinical stagecardiac amyloidosistherapeutic candidatedrug discoveryrare disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attralus Comps

Public and private peers based on sector, stage, and business model.

Attralus comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Attralus Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 6, 2024
Series BSep 8, 2021
Series ASep 14, 2020

Key People

Founding team and executive leadership

Mark Timney

CEO Board Member, Attralus Therapeutics

Executive Team

Spencer Guthrie

Chief Executive Officer

Executive Team

Attralus Investors

Notable investors and investment history

Attralus investors
InvestorRounds
Redmile GroupSeries B
Surveyor CapitalSeries B Extension, Series B
Janus Henderson GroupSeries B
Logos CapitalSeries B Extension, Series B
CitadelSeries B Extension, Series B
venBioSeries B Extension, Series B, Series A
Samsara BioCapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 8, 2021

    $116M round led by Logos Capital.

Attralus Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Attralus Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Attralus's valuation, stock price, and market status.

Firmographic Details

HeadquartersNaples, Florida
Employee Range21
Year Founded2019
Last FundingFeb 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.